MEDP vs NTRA
Medpace vs Natera, Inc. — AI-powered side-by-side comparison
| Metric | MEDP | NTRA |
|---|
| AI Score |
67
|
67
|
| Price |
$578.86
|
$309.83
|
| P/E Ratio |
33.46×
|
-228.51×
|
| ROE |
98.3%
|
-12.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
65.3%
|
| Debt / Equity |
0.28×
|
0.13×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
48.8
|
66.7
|
| Beta |
1.151
|
1.514
|
| Expected Upside |
+7.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for MEDP versus NTRA.
The committee scores are tied.
MEDP and NTRA both score 67/100.
MEDP Committee View
67% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is p/e of 33.1 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.1 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 33.7% signals elevated volatility — Risk